Arbutus Biopharma Corp ABUS
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
Arbutus Biopharma Corp (ABUS) is a healthcare company listed in the US with a market value of about $627M. In the twelve months to September 30, 2026 it had revenue of $181M and net income of $220M, a net margin of 121.2%.
Its overall Stock Analiz score is 2.6 out of 5 (average). The strongest part is value (4/5); the weakest is track record (1/5).
Key numbers: a P/E of 3.6, a price to free cash flow of 2.8, 5-year revenue growth of 15% a year, a 5-year average ROIC of -46%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 126% above the current price.
About Arbutus Biopharma
Arbutus Biopharma is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $15M in 2014 to $14M in 2025, a decline of about 0.5% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 27% over three years (dilution for shareholders). It spends 179% of revenue on research and development.
Score: 2.6 / 5
Checks passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- Revenue growth above 10% last year
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
Checks not passed
- PEG below 1.5
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year average ROIC above 12%
- Profitable 5 years in a row
- ROE above 15%
- Interest covered more than 5 times
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $181M | $14M | $6M | $18M | $39M | $11M | $7M | $6M | $6M | $11M | $1M |
| Net income | $220M | -$34M | -$70M | -$73M | -$69M | -$76M | -$64M | -$154M | -$57M | -$84M | -$384M |
| Free cash flow | $221M | -$40M | -$65M | -$87M | -$36M | -$68M | -$52M | -$72M | -$69M | -$56M | -$62M |
| EPS (diluted) | $1.13 | $-0.17 | $-0.38 | $-0.44 | $-0.46 | $-0.83 | $-1.00 | $-2.89 | $-1.21 | $-1.56 | $-7.24 |
| Net margin | 121.2% | -237.9% | -1133.0% | -401.6% | -178.0% | -693.9% | -922.0% | -2557.4% | -959.8% | -788.9% | -25765.5% |
| ROIC | — | -39.0% | -61.1% | -57.2% | -37.2% | -33.8% | -55.1% | -174.7% | -41.7% | -47.2% | -190.2% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 1 analysts is $5.34, 31% above the current price; targets range from $5.34 to $5.34; the consensus rating is “none”; expected EPS is $1.03 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Arbutus Biopharma’s P/E ratio?
About 3.6, based on the last twelve months of diluted earnings per share (forward P/E about 139.6).
Is Arbutus Biopharma stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 126% above the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Arbutus Biopharma pay a dividend?
Not currently.
Is Arbutus Biopharma a good stock to buy?
We do not give buy or sell advice. Arbutus Biopharma scores 2.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.